Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.

Summary: For people with Type 2 Diabetes, taking Metformin is often the first line of defense, but sometimes it isn't enough to keep blood sugar in check. A new extensive analysis looked at 11 different versions of a drug class called SGLT2 inhibitors (often known as "gliflozins") to see which ones worked best when added to Metformin. The study found that these drugs are generally safe and effective at lowering blood sugar and helping with weight loss. Among all the options tested, a higher dose of Canagliflozin (300 mg) stood out as the best overall choice for improving glucose levels and shedding pounds without causing serious safety issues, though patients should watch out for minor infections.